(BON) Bon Natural Life - Ratings and Ratios

Exchange: NASDAQ • Country: China • Currency: USD • Type: Common Stock • ISIN: KYG144921056

Natural Ingredients, Fragrance Compounds, Health Supplements

BON EPS (Earnings per Share)

EPS (Earnings per Share) of BON over the last years for every Quarter: "2020-03": 2.97, "2020-09": 2.84, "2021-06": 3.99, "2021-12": 2.99, "2022-03": 3.04, "2022-06": 2.19, "2022-12": 4.39, "2023-03": 2.36, "2023-06": 2.63, "2023-09": 2.63, "2023-12": -0, "2024-03": -0.01, "2024-12": 0.22,

BON Revenue

Revenue of BON over the last years for every Quarter: 2020-03: 7.149785, 2020-09: 11.070174, 2021-06: 11.69883, 2021-12: 13.795734, 2022-03: 13.6884, 2022-06: 8.11008, 2022-12: 16.220161, 2023-03: 14.149967, 2023-06: 15.372386, 2023-09: 15.372386, 2023-12: 5.091777, 2024-03: 10.183554, 2024-12: 13.661003,

Description: BON Bon Natural Life

Bon Natural Life Limited is a China-based company that specializes in extracting and manufacturing functional active ingredients from natural herbs, catering to various industries such as personal care, cosmetics, pharmaceuticals, and functional food. Their product portfolio includes plant-extracted fragrance compounds, natural health supplements, and bioactive food ingredients. With a global customer base, the companys products are utilized by manufacturers in multiple sectors.

Further analysis reveals that Bon Natural Life has been in operation since 2006, with its headquarters in Xian, China. The company has a strong presence in the natural ingredients market, with a diverse range of products that are used in various applications. The companys business model is focused on research and development, manufacturing, and sales, indicating a high level of vertical integration.

From a market perspective, Bon Natural Lifes stock has experienced significant volatility, with a 52-week high of $73.35 and a low of $1.30. The current price of $1.80 is above the 20-day simple moving average (SMA) of $1.54, indicating a potential short-term uptrend. However, the stock is still far below its 50-day SMA of $3.25 and 200-day SMA of $29.82, suggesting a longer-term downtrend.

Using technical and fundamental data, a forecast for Bon Natural Lifes stock can be made. The low P/E ratio of 0.49 and forward P/E of 2.35 suggest that the stock may be undervalued. Additionally, the relatively low market capitalization of $7.89M USD indicates a small-cap stock with potential for growth. However, the high volatility (ATR = 7.90%) and low return on equity (RoE = 7.12%) are concerns that need to be addressed. Based on these factors, a potential trading strategy could be to buy the stock on a sustained move above $2.00, with a target price of $3.50 in the short term, and $5.00 in the long term, contingent on the companys ability to improve its profitability and reduce volatility.

Additional Sources for BON Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

BON Stock Overview

Market Cap in USD 9m
Sector Basic Materials
Industry Specialty Chemicals
GiC Sub-Industry Packaged Foods & Meats
IPO / Inception 2021-06-24

BON Stock Ratings

Growth Rating -85.0
Fundamental -28.2
Dividend Rating 0.0
Rel. Strength -98.1
Analysts -
Fair Price Momentum 1.21 USD
Fair Price DCF -

BON Dividends

Currently no dividends paid

BON Growth Ratios

Growth Correlation 3m -27.2%
Growth Correlation 12m -93.6%
Growth Correlation 5y -98.6%
CAGR 5y -83.69%
CAGR/Max DD 5y -0.84
Sharpe Ratio 12m -1.26
Alpha -125.99
Beta 2.277
Volatility 118.08%
Current Volume 160.5k
Average Volume 20d 412.4k
What is the price of BON shares?
As of July 02, 2025, the stock is trading at USD 1.23 with a total of 160,472 shares traded.
Over the past week, the price has changed by -13.38%, over one month by -23.13%, over three months by -42.79% and over the past year by -97.94%.
Is Bon Natural Life a good stock to buy?
Probably not. Based on ValueRay´s Fundamental Analyses, Bon Natural Life (NASDAQ:BON) is currently (July 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.23 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BON is around 1.21 USD . This means that BON is currently overvalued and has a potential downside of -1.63%.
Is BON a buy, sell or hold?
Bon Natural Life has no consensus analysts rating.
What are the forecasts for BON share price target?
According to our own proprietary Forecast Model, BON Bon Natural Life will be worth about 1.4 in July 2026. The stock is currently trading at 1.23. This means that the stock has a potential upside of +16.26%.
Issuer Target Up/Down from current
Wallstreet Target Price 77.5 6200.8%
Analysts Target Price - -
ValueRay Target Price 1.4 16.3%